Martins, Filipe Correia http://orcid.org/0000-0001-6459-8206
Couturier, Dominique-Laurent http://orcid.org/0000-0001-5774-5036
de Santiago, Ines http://orcid.org/0000-0002-8172-1322
Sauer, Carolin Margarethe http://orcid.org/0000-0003-2168-6630
Vias, Maria
Angelova, Mihaela http://orcid.org/0000-0002-0495-9695
Sanders, Deborah
Piskorz, Anna
Hall, James
Hosking, Karen
Amirthanayagam, Anumithra
Cosulich, Sabina
Carnevalli, Larissa http://orcid.org/0000-0001-7432-0195
Davies, Barry http://orcid.org/0000-0002-5414-9113
Watkins, Thomas B. K.
Funingana, Ionut G. http://orcid.org/0000-0002-1197-2652
Bolton, Helen
Haldar, Krishnayan
Latimer, John
Baldwin, Peter
Crawford, Robin
Eldridge, Matthew http://orcid.org/0000-0002-5799-8911
Basu, Bristi http://orcid.org/0000-0002-3562-2868
Jimenez-Linan, Mercedes
Mcpherson, Andrew W.
McGranahan, Nicholas
Litchfield, Kevin http://orcid.org/0000-0002-3725-0914
Shah, Sohrab P. http://orcid.org/0000-0001-6402-523X
McNeish, Iain http://orcid.org/0000-0002-9387-7586
Caldas, Carlos http://orcid.org/0000-0003-3547-1489
Evan, Gerard http://orcid.org/0000-0003-0412-1216
Swanton, Charles http://orcid.org/0000-0002-4299-3018
Brenton, James D. http://orcid.org/0000-0002-5738-6683
Funding for this research was provided by:
Cancer Research UK (C53876/A24267)
Academy of Medical Sciences (SGL016_1084)
CUH | Addenbrooke’s Charitable Trust, Cambridge University Hospitals (REF 13/17)
Article History
Received: 17 December 2021
Accepted: 6 October 2022
First Online: 26 October 2022
Competing interests
: The Experimental Medicine Initiative from the University of Cambridge that funded F.C.M. Clinical Lectureship is partly funded by Astrazeneca. C.C. is a member of the AstraZeneca (AZ) External Science Panel, and has research grants from Roche, Genentech, AZ, and Servier that are administered by the University of Cambridge and reports receiving speakers’ bureau honoraria from Illumina. C.S. acknowledges grant support from Pfizer, AstraZeneca, Bristol Myers Squibb, Roche-Ventana, Boehringer-Ingelheim, Invitae (previously Archer Dx Inc - collaboration in minimal residual disease sequencing technologies) and Ono Pharmaceutical. He is an AstraZeneca Advisory Board member and Chief Investigator for the AZ MeRmaiD 1 and 2 clinical trials and is also Co-Chief Investigator of the NHS Galleri trial funded by GRAIL and a paid member of GRAIL’s Scientific Advisory Board. He receives consultant fees from Achilles Therapeutics (also SAB member), Bicycle Therapeutics (also a SAB member), Genentech, Medicxi, Roche Innovation Centre – Shanghai, Metabomed (until July 2022), and the Sarah Canon Research Institute C.S. has received honoraria from Amgen, AstraZeneca, Pfizer, Novartis, GlaxoSmithKline, MSD, Bristol Myers Squibb, Illumina, and Roche-Ventana. C.S. had stock options in Apogen Biotechnologies and GRAIL until June 2021, and currently has stock options in Epic Bioscience, Bicycle Therapeutics, and has stock options and is co-founder of Achilles Therapeutics. C.S. holds patents relating to assay technology to detect tumour recurrence (PCT/GB2017/053289); targeting neoantigens (PCT/EP2016/059401), identifying patent response to immune checkpoint blockade (PCT/EP2016/071471), determining HLA LOH (PCT/GB2018/052004), predicting survival rates of patients with cancer (PCT/GB2020/050221), identifying patients who respond to cancer treatment (PCT/GB2018/051912), US patent relating to detecting tumour mutations (PCT/US2017/28013), methods for lung cancer detection (US20190106751A1) and both a European and US patent related to identifying insertion/deletion mutation targets (PCT/GB2018/051892). J.D.B. has stock options in Tailor Bio and Inivata and is co-founder of Tailor Bio. J.D.B. has had consulting and advisory roles in AstraZeneca and Clovis Oncology and has received honoraria from GSK and Astrazeneca. J.D.B. holds patents relating to TAm-Seq v2 method for ctDNA estimation, enhanced detection of target DNA by fragment size analysis and methods for predicting treatment response in cancers. The remaining authors declare no competing interests.